Ebola virus vaccines – reality or fiction?

Chad Mire, Thomas Geisbert, Heinz Feldmann, Andrea Marzi

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

For 40 years ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates. In December 2013 an unprecedented Zaire ebolavirus epidemic began in West Africa. Although “patient zero” has finally been reached after 2 years, the virus is again causing disease in the region. Currently there are no licensed vaccines or therapeutic countermeasures against ebolaviruses; however, the epidemic in West Africa has focused attention on the potential vaccine platforms developed over the past 15 years. There has been remarkable progress using a variety of platforms including DNA, subunit, and several viral vector approaches, replicating and non-replicating, which have shown varying degrees of protective efficacy in the “gold-standard” nonhuman primate models for Ebolavirus infections. A number of these vaccine platforms have moved into clinical trials over the past year with the hope of finding an efficacious vaccine to prevent future outbreaks/epidemics of Ebola hemorrhagic fever on the scale of the West African epidemic.

Original languageEnglish (US)
Pages (from-to)1421-1430
Number of pages10
JournalExpert Review of Vaccines
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Ebola Vaccines
Ebolavirus
Vaccines
Western Africa
Primates
Disease Outbreaks
Ebola Hemorrhagic Fever
Hemorrhagic Fever with Renal Syndrome
Democratic Republic of the Congo
Gold
Fever
Clinical Trials
Viruses
DNA
Infection

Keywords

  • animal model
  • Ebolavirus
  • filovirus
  • prophylaxis
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Ebola virus vaccines – reality or fiction? / Mire, Chad; Geisbert, Thomas; Feldmann, Heinz; Marzi, Andrea.

In: Expert Review of Vaccines, Vol. 15, No. 11, 01.11.2016, p. 1421-1430.

Research output: Contribution to journalReview article

Mire, Chad ; Geisbert, Thomas ; Feldmann, Heinz ; Marzi, Andrea. / Ebola virus vaccines – reality or fiction?. In: Expert Review of Vaccines. 2016 ; Vol. 15, No. 11. pp. 1421-1430.
@article{7d6b20ffb0c448f19e0c6670614f7094,
title = "Ebola virus vaccines – reality or fiction?",
abstract = "For 40 years ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates. In December 2013 an unprecedented Zaire ebolavirus epidemic began in West Africa. Although “patient zero” has finally been reached after 2 years, the virus is again causing disease in the region. Currently there are no licensed vaccines or therapeutic countermeasures against ebolaviruses; however, the epidemic in West Africa has focused attention on the potential vaccine platforms developed over the past 15 years. There has been remarkable progress using a variety of platforms including DNA, subunit, and several viral vector approaches, replicating and non-replicating, which have shown varying degrees of protective efficacy in the “gold-standard” nonhuman primate models for Ebolavirus infections. A number of these vaccine platforms have moved into clinical trials over the past year with the hope of finding an efficacious vaccine to prevent future outbreaks/epidemics of Ebola hemorrhagic fever on the scale of the West African epidemic.",
keywords = "animal model, Ebolavirus, filovirus, prophylaxis, vaccine",
author = "Chad Mire and Thomas Geisbert and Heinz Feldmann and Andrea Marzi",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14760584.2016.1178068",
language = "English (US)",
volume = "15",
pages = "1421--1430",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Ebola virus vaccines – reality or fiction?

AU - Mire, Chad

AU - Geisbert, Thomas

AU - Feldmann, Heinz

AU - Marzi, Andrea

PY - 2016/11/1

Y1 - 2016/11/1

N2 - For 40 years ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates. In December 2013 an unprecedented Zaire ebolavirus epidemic began in West Africa. Although “patient zero” has finally been reached after 2 years, the virus is again causing disease in the region. Currently there are no licensed vaccines or therapeutic countermeasures against ebolaviruses; however, the epidemic in West Africa has focused attention on the potential vaccine platforms developed over the past 15 years. There has been remarkable progress using a variety of platforms including DNA, subunit, and several viral vector approaches, replicating and non-replicating, which have shown varying degrees of protective efficacy in the “gold-standard” nonhuman primate models for Ebolavirus infections. A number of these vaccine platforms have moved into clinical trials over the past year with the hope of finding an efficacious vaccine to prevent future outbreaks/epidemics of Ebola hemorrhagic fever on the scale of the West African epidemic.

AB - For 40 years ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates. In December 2013 an unprecedented Zaire ebolavirus epidemic began in West Africa. Although “patient zero” has finally been reached after 2 years, the virus is again causing disease in the region. Currently there are no licensed vaccines or therapeutic countermeasures against ebolaviruses; however, the epidemic in West Africa has focused attention on the potential vaccine platforms developed over the past 15 years. There has been remarkable progress using a variety of platforms including DNA, subunit, and several viral vector approaches, replicating and non-replicating, which have shown varying degrees of protective efficacy in the “gold-standard” nonhuman primate models for Ebolavirus infections. A number of these vaccine platforms have moved into clinical trials over the past year with the hope of finding an efficacious vaccine to prevent future outbreaks/epidemics of Ebola hemorrhagic fever on the scale of the West African epidemic.

KW - animal model

KW - Ebolavirus

KW - filovirus

KW - prophylaxis

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84991735020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991735020&partnerID=8YFLogxK

U2 - 10.1080/14760584.2016.1178068

DO - 10.1080/14760584.2016.1178068

M3 - Review article

C2 - 27078187

AN - SCOPUS:84991735020

VL - 15

SP - 1421

EP - 1430

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 11

ER -